48.28
price up icon0.90%   0.43
after-market Dopo l'orario di chiusura: 48.29 0.010 +0.02%
loading
Precedente Chiudi:
$47.85
Aprire:
$47.87
Volume 24 ore:
20.78M
Relative Volume:
1.45
Capitalizzazione di mercato:
$98.25B
Reddito:
$47.64B
Utile/perdita netta:
$5.42B
Rapporto P/E:
18.08
EPS:
2.67
Flusso di cassa netto:
$13.09B
1 W Prestazione:
+3.05%
1M Prestazione:
-1.91%
6M Prestazione:
-18.47%
1 anno Prestazione:
+19.95%
Intervallo 1D:
Value
$47.30
$48.35
Intervallo di 1 settimana:
Value
$46.10
$48.35
Portata 52W:
Value
$39.35
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Nome
Bristol Myers Squibb Co
Name
Telefono
(609) 252-4621
Name
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Dipendente
34,100
Name
Cinguettio
@BMSNEWS
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BMY's Discussions on Twitter

Confronta BMY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
48.28 95.34B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
737.67 640.72B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.21 367.98B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
186.11 323.71B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.76 222.69B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.50 299.26B 43.59B 15.04B 10.74B 3.3766

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-04-22 Iniziato Piper Sandler Overweight
2024-12-16 Aggiornamento Jefferies Hold → Buy
2024-12-10 Ripresa BofA Securities Neutral
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-13 Aggiornamento Daiwa Securities Neutral → Outperform
2024-11-12 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-25 Downgrade Citigroup Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-07-29 Downgrade Barclays Overweight → Equal Weight
2024-03-11 Downgrade Societe Generale Buy → Hold
2024-02-06 Downgrade Redburn Atlantic Buy → Neutral
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-02 Downgrade Daiwa Securities Outperform → Neutral
2023-10-27 Downgrade BMO Capital Markets Outperform → Market Perform
2023-10-27 Aggiornamento HSBC Securities Reduce → Hold
2023-10-27 Downgrade William Blair Outperform → Mkt Perform
2023-10-20 Ripresa UBS Neutral
2023-07-14 Iniziato HSBC Securities Reduce
2023-07-10 Iniziato SVB Securities Market Perform
2023-06-28 Iniziato Daiwa Securities Outperform
2023-03-06 Iniziato Jefferies Hold
2023-01-17 Iniziato Cantor Fitzgerald Overweight
2022-11-18 Iniziato Credit Suisse Neutral
2022-10-10 Downgrade Guggenheim Buy → Neutral
2022-09-14 Downgrade Berenberg Buy → Hold
2022-06-03 Downgrade Raymond James Outperform → Mkt Perform
2022-04-06 Ripresa Morgan Stanley Underweight
2021-12-17 Iniziato Goldman Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-11-01 Downgrade Argus Buy → Hold
2021-07-27 Ripresa Truist Buy
2021-04-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-04-13 Aggiornamento Truist Hold → Buy
2020-11-16 Aggiornamento Societe Generale Hold → Buy
2020-11-10 Ripresa Bernstein Mkt Perform
2020-11-06 Downgrade Gabelli & Co Buy → Hold
2020-10-19 Aggiornamento Guggenheim Neutral → Buy
2020-09-29 Iniziato Berenberg Buy
2020-07-28 Iniziato Raymond James Outperform
2020-04-02 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-01-06 Ripresa Citigroup Buy
2019-12-13 Aggiornamento Argus Hold → Buy
2019-11-22 Ripresa Morgan Stanley Equal-Weight
2019-10-17 Ripresa BofA/Merrill Buy
2019-08-14 Aggiornamento Atlantic Equities Neutral → Overweight
2019-05-28 Iniziato Goldman Buy
2019-05-20 Downgrade Argus Buy → Hold
2019-05-03 Aggiornamento Barclays Equal Weight → Overweight
2019-05-03 Ripresa JP Morgan Overweight
2019-01-15 Aggiornamento Societe Generale Sell → Buy
2018-10-22 Downgrade Citigroup Buy → Neutral
Mostra tutto

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

pulisher
May 30, 2025

BMO maintains Bristol-Myers Squibb stock at Market Perform By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BMO maintains Bristol-Myers Squibb stock at Market Perform - Investing.com

May 30, 2025
pulisher
May 30, 2025

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech - Endpoints News

May 30, 2025
pulisher
May 29, 2025

Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications - TradingView

May 29, 2025
pulisher
May 29, 2025

EC approval for BMS’ subcutaneous Opdivo - The Pharma Letter

May 29, 2025
pulisher
May 29, 2025

Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

EC approves BMS’ nivolumab SC formulation for solid tumours - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech

May 29, 2025
pulisher
May 29, 2025

Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividen - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple... - Medical Dialogues

May 29, 2025
pulisher
May 28, 2025

Bristol-Myers Squibb at Bernstein Conference: Strategic Growth and Innovation - Investing.com

May 28, 2025
pulisher
May 28, 2025

BMS says subcutaneous version of Opdivo gets EU nod - FirstWord Pharma

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividend Prospects - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - BioSpace

May 28, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

BMY Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Bristol Myers: EU green light for Opdivo subcutaneous injection - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Bristol Myers (BMY) Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications | BMY Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar (NYSE:BMY) - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5% (NYSE:BMY) - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

Bristol Myers Squibb’s SWOT analysis: stock faces challenges amid promising pipeline - Investing.com

May 27, 2025
pulisher
May 27, 2025

Deutsche Bank Accelerates Digital Transformation with IBM's Software Portfolio - The Globe and Mail

May 27, 2025
pulisher
May 26, 2025

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

May 26, 2025
pulisher
May 23, 2025

Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting - simplywall.st

May 23, 2025
pulisher
May 22, 2025

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Celgene Appeals Pennsylvania Tax After Bristol-Myers Acquisition - news.bloombergtax.com

May 22, 2025
pulisher
May 22, 2025

Areas of interest - Bristol Myers Squibb

May 22, 2025
pulisher
May 21, 2025

Bristol Myers, Novartis Take Drug Rebate Lawsuits to DC Circuit - Bloomberg Law News

May 21, 2025
pulisher
May 21, 2025

Tubulis achieves key milestone in BMS deal - The Pharma Letter

May 21, 2025
pulisher
May 20, 2025

Bristol Myers Squibb patents new BCL-6 degradation inducers - BioWorld MedTech

May 20, 2025
pulisher
May 20, 2025

Here's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

Bristol Myers Squibb patents new USP1 inhibitors - BioWorld MedTech

May 19, 2025
pulisher
May 18, 2025

Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN

May 18, 2025
pulisher
May 16, 2025

Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cance - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cancer Treatment - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Bristol Myers (BMY) Faces Market Movement Amid Medicare Part B & D Draft Guidance | BMY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Bristol-Myers Curbs Investor $6.4 Billion Payout Suit on Appeal - Bloomberg Law News

May 16, 2025
pulisher
May 16, 2025

Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom” - Insider Monkey

May 16, 2025
pulisher
May 16, 2025

BMY Gains EU Approval for Expanded Use of Opdivo in Lung Cancer Treatment | BMY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Reclaiming our time: Eightfold’s founder on the promise of agentic AI - HR Executive

May 16, 2025
pulisher
May 16, 2025

BMY Secures EC Approval for Opdivo Regimen in Lung Cancer Treatm - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Jim Cramer On Bristol-Myers Squibb: "Waiting For It To Bottom" - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN

May 15, 2025
pulisher
May 15, 2025

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - MSN

May 15, 2025
pulisher
May 15, 2025

Bristol Myers Squibb (BMY) CEO Calls for Fair Global Drug Pricin - GuruFocus

May 15, 2025

Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general PFE
$23.49
price up icon 0.17%
$110.08
price down icon 0.93%
$288.18
price up icon 1.64%
drug_manufacturers_general GSK
$41.03
price up icon 2.58%
drug_manufacturers_general MRK
$76.84
price up icon 0.58%
drug_manufacturers_general NVO
$71.50
price up icon 2.94%
Capitalizzazione:     |  Volume (24 ore):